An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia
About this trial
This is an interventional treatment trial for Acute Lymphoblastic Leukemia focused on measuring ALL, LBL, Asparaginase, Leukemia, Childhood acute lymphoblastic leukemia
Eligibility Criteria
Inclusion Criteria:
- Pediatric and adult patients with a diagnosis of ALL or LBL.
- Have had an allergic reaction to a long-acting E. coli-derived asparaginase OR have silent inactivation.
- Have 1 or more courses of E. coli-derived asparaginase remaining in his/her treatment plan.
- Patients must have, in the opinion of the Investigator, fully recovered from their prior allergic reaction to E. coli-derived asparaginase.
Exclusion Criteria:
- Have previously received asparaginase Erwinia chrysanthemi or JZP-458.
- Have relapsed ALL or LBL.
- Are concurrently receiving another investigational agent and/or treated with an investigational device at the same time as JZP-458 (within 48 hours) during Course 1 of JZP-458.
- Have a history of ≥ Grade 3 pancreatitis.
- Prior history of asparaginase-associated ≥ Grade 3 hemorrhagic event or asparaginase-associated thrombus requiring anticoagulation therapy, excluding catheter-related thrombotic events.
Sites / Locations
- Children's of Alabama
- Phoenix Children's Hospital
- Arkansas Children's Hospital
- Kaiser Permanente - Orange County - Anaheim Medical Center
- Kaiser Permanente - Downey Medical Center
- Kaiser Permanente - Fontana Medical Center
- Loma Linda University Medical Center
- MemorialCare Miller Children's and Women's Hospital Long Beach
- Children's Hospital Los Angeles
- Kaiser Permanente- Los Angeles Medical Center
- Benioff Children's Hospital Oakland
- Kaiser Permanente - Oakland Medical Center
- Children's Hospital of Orange County Main Campus - Orange
- Kaiser Permanente - Roseville Medical Center
- University of California Davis Comprehensive Cancer Center
- Kaiser Permanente - San Diego Medical Center
- University of California San Francisco Benioff Children's Hospital - Mission Bay
- Kaiser Permanente - Santa Clara Medical Center
- Connecticut Children's Medical Center
- Smilow Cancer Hospital - New Haven
- Nemours Alfred I. Dupont Hospital for Children
- Children's National Health System
- Golisano Children's Hospital of Southwest Florida
- Memorial Medical Office Centre
- Nemours Children's Specialty Care Jacksonville
- AdventHealth Orlando
- Johns Hopkins All Children's Hospital
- Scottish Rite Hospital
- Kapi'olani Medical Center for Women and Children
- Ann and Robert H. Lurie Children's Hospital of Chicago
- Norton Children's Hospital
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center
- C.S. Mott Children's Hospital
- Children's Minnesota
- Masonic Cancer Center
- University of Mississippi Medical Center
- Washington University School of Medicine in Saint Louis
- Alliance for Childhood Diseases
- Hackensack University Medical Center
- Morristown Medical Center
- Rutgers Cancer Institute of New Jersey
- Cohen Children's Medical Center
- NYU - Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders
- Herbert Irving Comprehensive Cancer Center
- Memorial Sloan-Kettering Cancer Center - New York
- Wake Forest Baptist Health
- Cincinnati Children's Hospital Medical Center
- Nationwide Children's Hospital
- The Children's Hospital at Oklahoma University Medical Center
- Oregon Health and Science University
- Children's Hospital of Philadelphia
- University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh
- Neurology Clinic, P.C
- East Tennessee Children's Hospital
- St. Jude Children's Research Hospital
- Vanderbilt University Medical Center
- Children's Blood and Cancer Center
- Medical City Dallas Hospital
- University of Texas Southwestern Medical Center
- Texas Children's Hospital
- Methodist Hospital - San Antonio
- Primary Children's Hospital
- Inova Medical Group - Fairfax Hospital
- Children's Hospital of The King's Daughters
- Massey Cancer Center
- Seattle Children's Hospital
- Providence Sacred Heart Medical Center
- CancerCare Manitoba - McDermot and Urgent Care Site
- McMaster Children's Hospital
- Victoria Hospital & Children's Hospital
- Children's Hospital of Eastern Ontario
- SickKids - The Hospital for Sick Children
- Centre Hospitalier Universitaire Sainte-Justine
- The Montreal Children's Hospital
Arms of the Study
Arm 1
Experimental
JZP-458
Part A (IM JZP-458) of the study will have 2 IM cohorts: Cohort 1: a JZP-458 repeat dose/confirmatory cohort; a final IM JZP-458 dose level will be selected, and Cohort 2: an expansion cohort to confirm the efficacy and safety of the final IM JZP-458 dose level and schedule Part B (IV JZP-458 Dose Confirmation) will be conducted to define the optimal dose of the IV administration of JZP-458 for further study in ALL/LBL patients as a repeated dose. Additional courses of JZP-458 (IM or IV depending on patient's allocation at study enrollment) will be administered based on each patient's original treatment plan for as long as the patient derives clinical benefit.